Journal: Breast cancer research and treatment

Article Title: Viral transduction of the HER2-extracellular domain expands trastuzumab-based photoimmunotherapy for HER2-negative breast cancer cells.

doi: 10.1007/s10549-015-3265-y

Figure Lengend Snippet: Fig. 1 HER2-extracellular domain (ECD) expression induced by Ad- HER2-ECD. a Western blot analysis showing expression of the 100-kDa HER2-ECD protein in Ad-HER2-ECD-infected cells but not in Ad-GFP-infected or parental cells. Actin was used as a loading control. b Flowcytometric analysis showing HER2-ECD expression on the cell membrane. Cells were labeled with APC-conjugated

Article Snippet: In experiments with replication-deficient adenoviral vector, cells were infected with Ad-HER2-ECD or Ad-GFP at a multiplicity of infection (MOI) of 50 for 48 h. Flowcytometric analysis To measure the expression of HER2-ECD in cells infected with Ad-HER2-ECD, cells were labeled with APC-conjugated mouse monoclonal anti-HER2-ECD antibody (R&D Systems Inc.) or APC-conjugated IgG2b as control (Miltenyi Biotec, Inc.) on ice for 45 min and were then analyzed using a FACS instrument (BD Biosciences).

Techniques: Expressing, Western Blot, Infection, Control, Membrane, Labeling

Journal: Breast cancer research and treatment

Article Title: Viral transduction of the HER2-extracellular domain expands trastuzumab-based photoimmunotherapy for HER2-negative breast cancer cells.

doi: 10.1007/s10549-015-3265-y

Figure Lengend Snippet: Fig. 2 Trastzumab-IR700 binds to the transduced cell surface HER2- ECD Immunofluorescent analysis of Trastzumab-IR700 (Tra-IR700) binding to HER2-ECD-transduced by Ad-HER2-ECD on the cell surface of breast cancer cells. Scale bars 50 lm

Article Snippet: In experiments with replication-deficient adenoviral vector, cells were infected with Ad-HER2-ECD or Ad-GFP at a multiplicity of infection (MOI) of 50 for 48 h. Flowcytometric analysis To measure the expression of HER2-ECD in cells infected with Ad-HER2-ECD, cells were labeled with APC-conjugated mouse monoclonal anti-HER2-ECD antibody (R&D Systems Inc.) or APC-conjugated IgG2b as control (Miltenyi Biotec, Inc.) on ice for 45 min and were then analyzed using a FACS instrument (BD Biosciences).

Techniques: Binding Assay

Journal: Breast cancer research and treatment

Article Title: Viral transduction of the HER2-extracellular domain expands trastuzumab-based photoimmunotherapy for HER2-negative breast cancer cells.

doi: 10.1007/s10549-015-3265-y

Figure Lengend Snippet: Fig. 3 Microscopic analysis of the effect of Tra-IR700-mediated PIT on the cell morphology and cell death of HER2-ECD-transduced HER2-negative cells. a Phase contrast analysis of the morphology of the breast cancer cells MCF-7 and MDA-MB-231 immediately following PIT using 0, 6, or 18 J. Scale bars 50 lm. b Phase contrast analysis of control, Ad-GFP-infected or Ad-HER2-ECD-infected MCF-7 and MDA-MB-231 cells before and after 72 h treatment with

Article Snippet: In experiments with replication-deficient adenoviral vector, cells were infected with Ad-HER2-ECD or Ad-GFP at a multiplicity of infection (MOI) of 50 for 48 h. Flowcytometric analysis To measure the expression of HER2-ECD in cells infected with Ad-HER2-ECD, cells were labeled with APC-conjugated mouse monoclonal anti-HER2-ECD antibody (R&D Systems Inc.) or APC-conjugated IgG2b as control (Miltenyi Biotec, Inc.) on ice for 45 min and were then analyzed using a FACS instrument (BD Biosciences).

Techniques: Control, Infection

Journal: Breast cancer research and treatment

Article Title: Viral transduction of the HER2-extracellular domain expands trastuzumab-based photoimmunotherapy for HER2-negative breast cancer cells.

doi: 10.1007/s10549-015-3265-y

Figure Lengend Snippet: Fig. 4 Effect of Tra-IR700 mediated PIT treatment of HER2-ECD transduced HER2-negative cells on cell viability. Tra-IR700-medi- ated PIT was applied to the indicated cells along with seven control conditions and cell viability was quantified 72 h after PIT (24 J for MDA-MB-231 and 36 J for MCF-7) using the XTT assay. Only the

Article Snippet: In experiments with replication-deficient adenoviral vector, cells were infected with Ad-HER2-ECD or Ad-GFP at a multiplicity of infection (MOI) of 50 for 48 h. Flowcytometric analysis To measure the expression of HER2-ECD in cells infected with Ad-HER2-ECD, cells were labeled with APC-conjugated mouse monoclonal anti-HER2-ECD antibody (R&D Systems Inc.) or APC-conjugated IgG2b as control (Miltenyi Biotec, Inc.) on ice for 45 min and were then analyzed using a FACS instrument (BD Biosciences).

Techniques: Control, XTT Assay